ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM) that binds to the ATP-binding pocket of IRAK4; it targets the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) harboring the MYD88L265P mutation; it inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and prevents gout formation in mouse models.